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1. Introduction 
Glaucoma remains one of the leading causes of blindness worldwide. In England and Wales 
glaucoma is a major or contributory factor for 12-14% of all registrations for blindness and 
partial sight, second only to macular degeneration (Bunce et al., 2010). The worldwide 
burden is more significant, with glaucoma being the second leading cause of global 
blindness after cataract (Resnikoff et al., 2004). It has been estimated that 60.5 million people 
worldwide would be affected by glaucoma by 2010, with the figure expected to rise to 80 
million by 2020 (Quigley and Broman, 2006). 
Current treatments for glaucoma comprise the lowering of intraocular pressure by eye 
drops, laser procedures or drainage surgery. However, as implied by the statistics above, 
many patients experience significant visual loss due to degeneration of retinal ganglion cells 
(RGCs) despite the advances in the treatments currently available. The need for novel 
therapies exists for such patients, in particular those with end stage glaucoma, where the 
maintenance of a small number of surviving RGCs may yet permit a reasonable quality of 
life (Much et al., 2008). Stem cell therapies developed in the laboratory and translated to 
clinical practice provide an exciting and realistic hope for those affected by degenerative 
retinal diseases including glaucoma. This chapter will discuss three mechanisms by which 
stem cell therapies may potentially offer hope to patients with end stage glaucoma, namely 
local RGC replacement, optic nerve regeneration and stem cell mediated neuroprotection. 
2. Sources of stem cells 
Stem cells are characterised by their capacity for unlimited self-renewal and ability to 
differentiate into different cell types. The term progenitor cell is often applied to multipotent 
cells with a capacity for self-renewal, however this chapter will use the term stem cell to 
encompass all progenitor and precursor cell types. 
An ideal candidate for developing stem cell based therapies would be readily available, easy 
to expand in culture, possess an acceptable long term safety profile and be autologous in 
nature, in order to avoid the need to modulate the host immune response and prevent 
rejection. Unfortunately a cell type that fulfils all these criteria remains elusive, however 
current research is directed towards a limited number of cell types which themselves exhibit 
certain advantages or disadvantages. Such cell populations may be sourced from three 
broad categories – embryonic or foetal tissue, adult tissue and reprogrammed cells  
(Figure 1). 
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Fig. 1. Summary of the sources of cells that may be potentially used for cell based therapies 
in glaucoma. (Figure composed using Motifolio Inc. diagrams) 
2.1 Embryonic stem cells 
Embryonic stem cells (ESCs) arise from the inner cell mass of the blastocyst, which is formed 
at about five days after fertilisation in humans. Such cells are often sourced from excess 
tissue obtained from embryo donations and fertility treatments and have been associated 
with ethical objections due to controversies regarding the use of such tissue for research. 
However they possess an unlimited capacity for self-renewal with an ability to differentiate 
into any of the cell types within the human body (Evans and Kaufman, 1981). ESCs have 
been proposed as ideal candidates for cell based therapies to treat human retinal diseases, 
due their capacity to migrate and differentiate into different cell types. ESCs have been 
differentiated in vitro into neurons (Bibel et al., 2004) as well as retinal pigmented epithelium 
(RPE) (Hirano et al., 2003), but controlling their differentiation has proved challenging. In 
the absence of appropriate intracellular signals, ESCs appear to differentiate towards a 
neuronal fate by default (Hemmati-Brivanlou and Melton, 1997), although differentiation 
into retina specific precursors often involves complex laboratory protocols (Osakada et al., 
2009). A drawback of a pluripotent cell type is the risk of teratoma formation by 
uncontrolled growth of transplanted ESCs (Hentze et al., 2007) which remains a major 
concern. In addition, safety concerns derived from the observed chromosomal instability of 
cultured ESCs (Moon et al., 2011) require further investigation. 
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2.2 Adult tissue-derived stem cells 
Adult tissue-derived stem cells offer an alternative for the development of cell based 
therapies which circumvents the ethical controversies surrounding foetal and embryonic 
tissue. Up to date, various sources of adult stem cells have been investigated for their 
potential ability to regenerate or replace retinal neurons which are described below. 
2.2.1 Müller stem cells 
The concept of central nervous system (CNS) regeneration from glial cells has become more 
accepted in recent years. Radial glia within the brain have been shown to act as neural stem 
cells within the developing mammalian nervous system, with the ability to generate both 
new neurons and glia (Merkle et al., 2004). Müller glia are the radial glia of the retina and 
have been shown to share a common lineage with retinal neurons and to derive from a 
common multipotent progenitor (Turner and Cepko, 1987). Studies in zebrafish have 
demonstrated that the ability of this species to regenerate retina is due to the presence of 
Müller glia with stem cell characteristics (Bernardos et al., 2007). Pharmacological depletion 
of the ganglion cell layer has been shown to induce a regenerative response in this species, 
which is characterised by Müller glial cells re-entering the cell cycle and producing neuronal 
progenitor cells that repopulate the ganglion cell layer (Fimbel et al., 2007).  
Although a capacity for regeneration similar to that seen in the zebrafish has not been 
observed in higher species, a population of Müller glia with stem cell characteristics has 
been identified in the adult human retina (Lawrence et al., 2007). These cells express 
markers of neural progenitors in vitro and a proportion of them are able to express markers 
of mature retinal neurons in response to various culture conditions (Lawrence et al., 2007). 
Data from our laboratory exploring transplantation of these cells in a rodent model of 
ganglion cell depletion shows that pre-differentiated cells are able to integrate within the 
host RGC layer and cause partial restoration of the scotopic threshold response, which is a 
marker of RGC function in the rat electroretinogram (Singhal et al., 2009). 
Such cell lines are easily obtained from cadaveric donor retinae (Limb et al., 2002) and 
further studies may reveal whether it is possible to obtain patient specific cell lines from 
peripheral retinal biopsies, leading to the possibility of developing an autologous grafting 
strategy. 
2.2.2 Mesenchymal stem cells 
Mesenchymal stem cells are most commonly obtained from bone marrow biopsies and 
umbilical cord blood and have been considered as candidates for autologous cell 
transplantation. Pharmacological methods have been used to mobilise haematopoetic stem 
cells from the bone marrow into the bloodstream to facilitate their harvesting for 
transplantation (Uy et al., 2008) rather than employing more invasive bone marrow trephine 
techniques. The mobilisation of mesenchymal stem cells is more difficult than that of 
haematopoietic stem cells, with several strategies showing promise in animal models 
(Pitchford et al., 2009). During development mesenchymal stem cells differentiate into bone, 
cartilage and muscle. However they have been reported to de-differentiate in vitro into other 
cell types including neurons and glia, although at present there is much controversy 
surrounding this ability (Krabbe et al., 2005). As will be discussed later, this cell type is 
likely to have a more significant role in neuroprotective strategies rather than neuronal 
replacement, due to their ability to secrete cytokines. 
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2.2.3 Oligodendrocyte precursor cells 
Oligodendrocyte precursor cells (OPCs) are a type of neural stem cells responsible for the 
generation of oligodendrocytes during normal development, and for re-myelination of the 
white matter in the adult CNS (Watanabe et al., 2002). They are the commonest proliferative 
cell type in the adult CNS (Dawson et al., 2003). OPCs have been reported to exhibit some 
stem cell characteristics (Nunes et al., 2003) and neuroprotective potential in vitro (Wilkins et 
al., 2001), which have led to investigations into their potential use for stem cell based 
therapies to treat neurodegenerative conditions including glaucoma. 
2.2.4 Olfactory ensheathing cells 
Olfactory tissue is unique within the CNS, in that continuous removal and regeneration of 
tissue occurs throughout life. The sensory axons that project to the olfactory bulb are closely 
associated with specialised cells known as olfactory ensheathing cells (OECs). OECs are glial 
cells which lie within the nasal mucosa and olfactory bulb and characteristically ensheathe 
axons of the olfactory nerve. Transplantation of these cells has been used to support 
regenerating axons in animal models of spinal cord injury and to restore function (Li et al., 
2008). Due to the relative ease by which nasal mucosal biopsies may be obtained, these cells 
may potentially constitute a source of cells through which autologous transplantation 
strategies may be developed in the future. There is considerable molecular heterogeneity 
and functional diversity of OECs with much work still taking place in animal models (Su 
and He, 2010). Further investigation into the gene expression and cell fate determination of 
these cells will facilitate the development of more robust protocols to isolate and expand the 
OEC progenitor/stem cell population within this complex tissue. 
2.3 Induced pluripotent stem cells 
The characterisation of induced pluripotent stem cells (iPS) cells has created an alternative 
potential cell source for transplantation in regenerative medicine. Takahashi & Yamanaka 
(Takahashi and Yamanaka, 2006) demonstrated that by retroviral induction of Oct3/4, Sox2, 
c-Myc and Klf4, pluripotent stem cell lines could be derived from fibroblast cultures. 
Further study of these “reprogrammed” iPS cells showed that their biological behaviour 
was indistinguishable from that of ESCs (Wernig et al., 2007). Subsequent modifications to 
the original protocol have enabled iPS cell lines to be created without the use of viral vectors 
(Okita et al., 2008) and without induction of the oncogene c-Myc (Nakagawa et al., 2008) 
which may be associated with an increase in tumorigenesis. However before such cells can 
be used in human therapies, safety concerns regarding the effect of the reactivation of 
pluripotency, alterations in target cells and characterisation of these cells need to be 
addressed (Jalving and Shepers, 2009). 
3. Potential of stem cells for retinal ganglion cell replacement 
One of the strategies to restore vision in glaucoma patients after RGCs have been lost or 
irreversibly damaged is their functional replacement by autologous or heterologous 
transplantation. 
It is generally accepted that damage to the neural retina during glaucoma is restricted to the 
impairment of function and subsequently degeneration of RGCs (Kerrigan-Baumrind et al., 
2000; Quigley and Green, 1979), making these cells ideal candidates for early cell 
replacement strategies. Recent evidence indicates, however, that in addition to damage to 
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the optic nerve, prolonged elevation of intraocular pressure may also induce degeneration 
or loss of function of other retinal neural cell types, most notably of amacrine cells 
(Hernandez et al., 2009). Similar observations have been made in other retinal degenerative 
diseases such as retinitis pigmentosa, which is characterized not only by the loss of rod, but 
also of cone photoreceptors and by major morphological changes of other surviving retinal 
neurons (Fariss et al., 2000). Therefore early intervention may be preferable, if cell 
replacement strategies are to succeed, in order to restrict the number of cells types which 
need to be transplanted. In addition, the correct establishment of synaptic connections 
between transplanted RGC and native cells may be facilitated, providing that the stratified 
structure of the retina with its circuitry and at least some of the connections of the RGCs 
through the optic nerve and the optic chiasm to the lateral geniculate nucleus are preserved. 
At present, research has mostly focused on the identification of suitable cells, which can be 
differentiated towards RGCs and their precursors, as well as the experimental conditions 
required for the optimal expression of their molecular markers. Furthermore, a small 
number of studies have investigated the electrophysiological properties of the RGC 
precursors generated in vitro and their transplantation into in vivo models. Although 
research has been conducted into the functional replacement of RGCs, and potential 
candidate stem cells have been identified, there are currently no cell-based therapeutic 
options that are either available to patients or tested in clinical trials. Establishment of  
cell based therapies to replace or regenerate RGCs, as with any other cell based therapy, 
would require validation protocols for safety, efficacy and long term survival of the 
transplanted cells. In the following sections we will review the potential of human ES cells, 
iPS cells and adult human Müller stem cells for the generation and transplantation of RGCs 
and their precursors. 
3.1 Human embryonic stem cells as a prospective source of RGCs  
Most evidence for the differentiation of ESCs into retinal progenitors and their potential for 
retinal transplantation has been provided by animal studies. Murine ESCs have been shown 
to generate RGC-like cells in vitro by differentiation protocols using various growth and 
differentiating factors. This has resulted in the expression of markers such as Ath5, Brn3b, 
RPF-1, Thy-1 and Isl-1 (Jagatha et al., 2009), which are characteristically expressed by RGCs. 
Rx/rax-expressing murine ESCs, which were treated with retinoic acid to induce neural 
commitment, expressed markers of RGCs and horizontal cells, displayed 
electrophysiological properties consistent with RGCs and were able to integrate ex vivo into 
mouse retinae (Tabata et al., 2004). Importantly, when mouse ESCs, which had been 
differentiated into eye-like structures, were co-cultured with retinal explants following 
damage to the inner retinal cells, migration into the RGC layer as well as expression of the 
RGC markers HuD and Brn3b were observed (Aoki et al., 2007). 
Proof of concept that human ESCs can successfully differentiate into retinal neurons has 
been provided by xenologous transplantation. Following intravitreal injection into the adult 
mouse eye, human ESCs formed structures reminiscent of the developing optic cup and 
expressed markers of a wide range of retinal progenitors and neurons (Aoki et al., 2009). 
In addition transplanted murine ESCs have been shown to integrate into the inner and outer 
nuclear as well as the inner plexiform layers of the retinae of host mice with retinal 
degeneration. Transplanted cells adopted a morphology consistent with and displayed 
molecular markers of a wide range of retinal neurons, such as βIII-tubulin and NeuN, 
calretinin, PKC-α and rhodopsin (Meyer et al., 2006). 
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In addition, Lamba et al. have recently provided evidence that human ESCs can generate 
retinal progenitors with high efficiency, expressing a number of molecular markers usually 
observed in the developing retina. These cells have shown exceptional correlation between 
their levels of expression of genes specific for differentiating neurons and the developmental 
stage of the retina, including markers of RGC and amacrine cells, which constitute the inner 
retina, i.e. HuD/C, Pax6, neurofilament-M and Tuj1 (Lamba et al., 2006). 
Transplantation of human ESC-derived neural and retinal progenitors into animal models of 
retinal degeneration has been extensively studied by several groups. Neural precursors 
derived from human ESCs have been transplanted subretinally and intravitreally into mice, 
where they have been shown to be able to integrate into the retina and survive for long 
periods of time after grafting. Although these cells mostly displayed photoreceptors 
markers (Banin et al., 2006), such findings have provided evidence that human ESCs have 
the potential to form retinal neurons following engraftment. These results have been further 
supported by additional evidence that human ESCs can adopt a neural morphology and 
express neural retinal markers following transplantation and differentiating treatment in an 
in vivo murine model of RGC depletion, without giving rise to teratomas (Hara et al., 2010). 
Although human ESCs have shown potential for use in RGC replacement therapies for 
glaucoma, major disadvantages associated with the use of human ESCs still remain. Ethical 
constraints relating to the use of these cells, their limited availability and safety issues 
regarding teratoma formation are likely to curtail the translation of ESCs for human RGC 
replacement to the clinical setting. Further work should therefore be aimed towards 
identifying alternative sources of cells that may safely and efficiently replace these cells in 
the glaucomatous eye without these ethical and practical constraints.  
3.2 RGC differentiation of induced pluripotent stem cells 
Some of the disadvantages of human ESCs have been addressed by the development of iPS 
cells, which have been proposed as a viable source of cells for autologous transplantation. 
The generation of iPS cells does not require the destruction of embryonic tissue and 
therefore does not have the same ethical implications as work with ESCs, which have been a 
limitation in a large number of developed countries. In addition, iPS cells can be derived 
from and tailored to the patient, making cells more widely available and rendering 
immunosuppressive therapy following transplantation redundant. To date, few studies 
have investigated the potential for iPS cells in stem cell treatment of retinal degenerative 
diseases, although recently some progress has been made to generate iPS cell-derived RGC-
like cells.  
Parameswaran et al. have recently provided evidence that iPS cells, which originated from 
reprogrammed mouse embryonic fibroblasts by transfection with Oct3/4, Sox2, Klf4 and c-
Myc, can give rise to both RGCs and photoreceptors in vitro. They reported that neural 
induction and exposure to conditioned media from E14 rat retinal cells augmented the 
expression of Ath1, Brn3b, RPF1 and Irx2, which regulate RGC differentiation, while the 
retinal progenitor markers Sox2, Rx and Chx10 were reduced. Importantly, the same study 
reported that the generated RGC-like cells displayed tetrodotoxin-sensitive voltage-
dependent sodium currents, which is a hallmark of functional neurons (Parameswaran et 
al., 2010). 
Chen et al. have used a similar approach by creating iPS cells from reprogrammed murine 
fibroblasts, which had been transduced with Oct3/4, Sox2, c-Myc and Klf4, to generate 
RGC-like cells. These cells expressed markers of retinal progenitor cells, i.e. Pax6, Rx, Otx2, 
www.intechopen.com
 Stem Cell Based Therapies for Glaucoma 
 
275 
Lhx2 and nestin, the levels of which were attenuated after differentiation towards a RGC 
fate. Differentiation was accompanied by expression of markers of RGC progenitors such as 
Brn3b and Isl-1, as well as Thy-1.2, a marker of mature RGCs. However, transplanted cells 
did not engraft into murine retina following intravitreal injection and they retained their 
pluripotency as demonstrated by their ability to form intraocular teratomas (Chen et al., 
2010). 
These studies illustrate major problems associated with the transplantation of cells derived 
from iPS cells, which need to be addressed. In particular, as described by Chen et al., the 
ability of iPS to form teratomas and therefore their potential to form cancerous growths may 
prove problematic. These findings suggest that preparation of iPS cell derived RGC 
progenitors for individual patients may need to undergo extensive validation for safety and 
efficacy, making them likely to be impractical and expensive for autologous therapies.  
3.3 Müller stem cells as a source of RGCs for glaucoma therapies 
The lack of regenerative potential of the human retina in vivo may be due to presently 
unknown inhibitory factors within the fully developed retina, since human Müller glia cells 
with stem cell characteristics have been reported to retain the ability to divide indefinitely in 
vitro (Limb et al., 2002). Until further research can elucidate the nature of these inhibitory 
factors, it is however unlikely that treatment options involving re-activation of endogenous 
Müller stem cells in the adult human retina can be developed. Cell replacement by 
transplantation of Müller stem cell-derived retinal neural progenitors may therefore 
currently offer a more promising strategy to restore visual function after irreversible 
damage or substantial loss of RGCs in glaucoma. 
Müller glia with stem cell characteristics have been demonstrated to be predominantly 
located in the peripheral sections of the adult human retina (Bhatia et al., 2009). Human 
Müller stem cells can be easily isolated from cadaveric donor retina, and these cells can be 
grown and expanded indefinitely in vitro, and express markers of neural progenitor cells, 
such as Sox2, Notch1, Pax6, Shh and Chx10, as well as markers of Müller glia cells and 
retinal neurons e.g. CRALBP, HuD, PKC, and peripherin (Lawrence et al., 2007). When 
cultured under differentiating conditions in the presence of extracellular matrix and growth 
factors, enriched populations of cells expressing markers of specific retinal neurons can be 
obtained (Bhatia et al., 2011; Lawrence et al., 2007; Singhal et al., manuscript submitted).  
This is illustrated by the fact that Müller stem cells cultured under various conditions 
develop a neuronal morphology and upregulate their expression of retinal neural and RGC 
precursor markers such as βIII-tubulin, Brn3b, Isl-1 and rhodopsin. Simultaneously 
expression levels of the neural progenitor marker Pax6 and the glial cell marker vimentin 
are also attenuated (Bhatia et al., 2011), indicating that existing Müller stem cell lines may 
have the potential to form RGC precursors. 
However at present, intraocular transplantation studies using Müller stem cells have been 
conducted using mostly undifferentiated cells. Initially Lawence et al. reported integration 
of subretinally transplantated Müller stem cells into neonatal Lister Hooded rats and adult 
dystrophic RCS rats. Engrafted cells were shown to express the photoreceptor markers 
recoverin and rhodopsin, the RGC marker HuD as well as calretinin, which identifies RGCs 
and amacrine cells (Lawrence et al., 2007). Although integration of undifferentiated Müller 
stem cells has been observed after subretinal transplantation into adult dystrophic RCS rats, 
these cells were located in all retinal layers and did not selectively locate to the ganglion cell 
layer or adopt RGC-like morphology (Singhal et al., 2008). 
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Undifferentiated Müller stem cells have also been used for intravitreal and subretinal 
transplantation in a rat model of glaucoma. Although only few of the transplanted cells 
expressed the Müller glia and astrocyte marker GFAP, expression of βIII-tubulin indicates 
that at least some of the transplanted cells were able to adopt a neural phenotype. 
Interestingly, many of the grafted cells showed a migratory phenotype and aligned towards 
the host retina, in particular the optic nerve head, although they did not migrate and 
disseminate within the retina (Bull et al., 2008). 
Recently it has been reported that Müller stem cells can be differentiated into RGC 
precursors, which integrate into the retina after intravitreal injection and can partly restore 
function in RGC-depleted retina as measured by electroretinography (Singhal et al., 2009). 
Although at present understanding of Müller stem cell differentiation towards RGC 
precursors is limited, previous work with this cell type has shown that they may have the 
potential for therapeutic regeneration of RGC function in glaucoma. In particular the 
maturity of Müller stem cells may potentially decrease the risk of teratoma formation. In 
addition, their ontogenetic proximity to retinal neurons may likely facilitate the 
development of protocols not only to successfully derive and transplant RGC precursors, 
but also to induce endogenous retinal regeneration without the need for transplantation. 
3.4 Barriers to successful stem cell transplantation 
Although some progress has been made regarding the successful production, delivery, 
integration and survival of RGC progenitors, major obstacles for successful engraftment and 
functional restoration remain and will be discussed below. These include the host immune 
response and extracellular matrix, which form a barrier for cell integration into the healthy 
host retina. During retinal degenerative processes, there is abnormal deposition of 
extracellular matrix, mainly chondroitin sulphate proteoglycans, which are responsible for 
the formation of glial scarring (gliosis). In addition, accumulation of microglia occurs, which 
has been shown to surround transplanted cells, inhibit their migration and induce their 
death (Singhal et al., 2008). Additionally, effective migration and integration of the 
transplanted cells has been suggested to be dependent upon their ontogenetic stage 
(MacLaren et al., 2006). These requirements will be discussed in more detail below. 
3.4.1 Modulation of the host extracellular matrix 
Various transplantation studies using a wide range of cells derived from ESCs as well as 
Müller stem cells have concluded that successful engraftment into the healthy adult retina is 
impeded by extracellular matrix components and the physical barrier of the inner limiting 
membrane (Chacko et al., 2003; Johnson et al., 2010b). This is unlikely to be influenced by 
the route of cell delivery, since transplantation by either intravitreal or subretinal injection 
did not yield integration of transplanted cells into the healthy host retina in the adult rat 
(Bull et al., 2008). In addition dissemination of the transplanted cells within the retina has 
been reported to be highly restricted (Banin et al., 2006). Conversely, integration of 
transplanted cells has been demonstrated in neonates (Chacko et al., 2003) or in the adult 
retina following injury (Chacko et al., 2003), indicating that these environments may be 
more permissive for successful engraftment. 
Glaucomatous changes of the retina are generally accompanied by reactive gliosis as well as 
remodelling and deposition of extracellular matrix components (Guo et al., 2005). Increased 
production of chondroitin sulphate proteoglycans (CSPGs), which have been shown to 
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inhibit rat optic nerve regeneration after crush injury (Selles-Navarro et al., 2001) and reduce 
axonal and dendritic growth (Zuo et al., 1998), has been demonstrated following CNS and 
spinal cord damage (Bradbury et al., 2002). CSPGs have also been reported to form a barrier 
to cell migration following transplantation in animal models (Singhal et al., 2008) (Figure 2). 
Furthermore, degradation of CSPGs has been shown to enhance dendritic and axonal 
regeneration following brain and spinal cord injury (Bradbury et al., 2002; Zuo et al., 1998). 
As a result of these findings, the effects of modulation of extracellular matrix components have 
recently been explored in conjunction with retinal progenitor transplantation. Evidence has 
been provided to show that co-administration of chondroitinase ABC or erythropoietin, which 
has been reported to upregulate MMP-2 (Wang et al., 2006), greatly increases the number of 
cells, which successfully integrate into the host retina (Singhal et al., 2008; Suzuki et al., 2007). 
Similarly, the integration of murine neonatal retinal cells into the adult rat host retina by ex 
vivo transplantation has been shown to be augmented by the induction of MMP-2 (Suzuki et 
al., 2006).  
 
 
Fig. 2. Confocal imaging of rodent retina 2 weeks after subretinal transplantation of Müller 
stem cells. Sections on the left column shows the transplanted cells (green) surrounded by 
N-terminal CSPG, neurocan and versican (red). The middle column shows the same sections 
under Nomarski illumination to illustrate the accumulation of CD68 positive microglia 
(black). The column on the right shows the merged images under Nomarski illumination 
illustrating co-localization (arrows) of CD68 positive cells and CSPGs (red) surrounding the 
transplanted cells (green) (from Singhal et al., 2008). 
3.4.2 Modulation of the host immune response 
A successful transplantation scheme requires long term survival of the grafted cells. 
Allogeneic grafts induce a host immune response, leading to rejection and failure of the 
transplant. However cell survival is greatly increased by systemic immunosuppression of 
the recipient following allogeneic cell transplantation into the eye (West et al., 2010). Triple 
therapy with oral immunosuppressives has recently been used to increase survival of 
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xenografted Müller stem cells to 2 to 3 weeks, although microglia and macrophage 
activation was observed and transplants were destroyed after 4 weeks (Bull et al., 2008). 
Activation of phagocytic microglia, the resident immune cells of the CNS, which may 
promote axonal degeneration of RGCs and of the optic nerve, is frequently observed during 
glaucoma (Ebneter et al., 2010; Yuan and Neufeld, 2001). In transplantation models, 
microglia prevent the migration of transplanted cells into the retina (Singhal et al., 2008) 
(Figure 3). Suppression of the intraocular immune response and inhibition of microglial 
activation by intravitreal injection of triamcinolone acetonide may therefore promote the 
integration and the survival of RGC precursors into retinae with glaucomatous changes. 
Intravitreal injection of triamcinolone acetonide in combination with oral 
immunosuppression and anti-inflammatory medication has previously been shown to 
greatly reduce microglial activation against the xenograft (Singhal et al., 2008; Singhal et al., 
2010). 
 
 
Fig. 3. A. Müller stem cells (green) accumulate in the subretinal space and do not migrate 
into the retina. Middle image shows Nomarski illumination identifying CD68 positive cells 
(black) in the same retinal section. Right figure shows Nomarski illumination identifying co-
localization of transplanted cells with microglial cells expressing CD68 (black).  
B. Transplanted cells can be seen forming a large cluster in the subretinal space 2 weeks 
after transplantation. Middle image shows localization of microglia (black) around the 
transplanted cells (green). Right figure shows microglia (black) surrounding the 
transplanted cells (green) and resembling a granuloma-type structure (From Singhal et al., 
2008). 
In experimental animal models, immune-tolerization of embryos or neonates by 
intraperitoneal injection of grafted cells may be used to further reduce the host immune 
response (Billingham et al., 1953).  
3.4.3 Ontogenetic stage of transplanted cells 
Currently the role played by the ontogenetic stage of transplanted RGC precursors upon 
their integration into host retina, as well as on functionality of the engrafted cells, has not 
been investigated. Previous transplantation studies have demonstrated that stem cells 
isolated from adult individuals rarely migrated into the healthy adult retina (Johnson et al., 
2010a; Lawrence et al., 2007; Singhal et al., 2008), while embryonic and neonatal retinal 
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progenitors and other stem cells have been shown to successfully integrate into the host 
retina (Warfvinge et al., 2001; Wojciechowski et al., 2004), suggesting that the developmental 
stage of the transplant may be crucial for successful migration and functional integration. 
Several studies have investigated the role of the developmental stage of grafted retinal 
neurons for successful incorporation into the host retina. Based on this work, it has been 
concluded at least in the case of photoreceptor transplantation that early postnatal post-
mitotic precursors or cells of a similar ontogenetic stage are the most promising candidates 
for transplantation in terms of their ability to migrate and disseminate into the retina and 
differentiate towards a functional phenotype (MacLaren et al., 2006).  
However, more recent studies have suggested that there may be no need for transplantation 
of photoreceptor progenitors for these cells to integrate, as fully mature photoreceptors 
retain the ability to integrate into the mature retina upon transplantation (Gust and Reh, 
2011). Moreover, integration of photoreceptors derived from human Müller glia into the 
degenerated rat retina has shown to be independent from NRL expression by these cells 
(Jayaram et al., unpublished observations).  
In addition the developmental phase of transplanted cells will likely have major 
implications on treatment safety, with less differentiated cells posing a greater risk of 
tumorigenesis. In fact, a number of studies using cells derived from embryonic stem or iPS 
cells have reported the occurrence of teratomas (Arnhold et al., 2004; Chen et al., 2010), 
whereas no formation of cancerous growths was reported after transplantation of adult-
derived stem cells. 
In summary, future research will be needed to elucidate the effects of the ontogenetic stage 
of transplanted RGC precursors on graft integration, function and safety.  
3.5 Strategies to measure functional outcome 
With the development of methods for the transplantation of RGC in glaucoma, the 
measurement of functional outcomes will become increasingly important. It can be 
anticipated, however, that these will encompass techniques currently available for the 
monitoring of disease progression. Electrophysiological measurements are widely used to 
assess glaucomatous damage both in patients and in experimental animal models and will 
likely continue to play a major role in evaluating treatment success. Some of these protocols 
have been standardized by the International Society for Clinical Electrophysiology of Vision 
(ISCEV) guidelines (Holder et al., 2007; Marmor et al., 2009), although they may be 
complemented by other methods established for laboratory use. 
The pattern ERG is currently one of the most useful techniques to assess glaucomatous 
damage in patients. It generally utilizes a black and white checkerboard stimulus with pattern 
reversal as prescribed by the ISCEV standards (Holder et al., 2007). The pattern ERG has been 
shown to be reduced in patients with glaucoma and correlates with visual field defects 
(Wanger and Persson, 1983). In addition the use of variable check sizes may be advisable to 
assess the extent of glaucomatous change (Bach et al., 1988). Recently multifocal pattern 
electroretinograms have been demonstrated to be reduced in glaucoma patients (Monteiro et 
al., 2011; Stiefelmeyer et al., 2004), although other studies have reported that localized 
reductions of the signal amplitude could not be correlated with visual field defects (Klistorner 
et al., 2000). Since this method requires good accommodation and fixation (Holder et al., 2007), 
it is widely used in human subjects, while its applicability to animal models is limited.  
Preclinical studies will likely favour methods employing Ganzfeld stimulation, which are 
relatively easy to apply to a laboratory setting. The most commonly used of these is the 
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scotopic threshold response, a low intensity light response with stimulation below the 
psychophysical threshold, which has be ascribed to RGC function, although it may species-
dependently contain contributions from amacrine cells (Frishman et al., 1996; Korth et al., 
1994; Sieving, 1991). More recently the photopic negative response has been established as a 
measure of RGC function (Viswanathan et al., 1999), although other cellular origins, such as 
glia and amacrine cells, have been suggested (Machida et al., 2008). However, at present this 
has not been assimilated into ISCEV guidelines. 
Pattern reversal, pattern onset/offset or flash visual evoked potentials can be used to assess 
RGC and optic nerve function. Although they are usually employed in a clinical setting 
(Odom et al., 2010), especially the flash, the pattern onset/offset visual evoked potentials 
may potentially be used for experimental applications in animals (Huang et al., 2011; Ver 
Hoeve et al., 1999). Recently multifocal mapping of visual evoked potentials has been 
developed (Hasegawa and Abe, 2001), but has not been widely applied to practice. 
However, for clinical purposes perimetry will remain important, as gains in the visual field 
of patients may indicate whether potential RGC cell therapies are successful.  
4. Optic nerve regeneration 
It has been considered critical for the functional success of RGC replacement therapies in 
glaucoma that transplanted cells form axons, restore the optic nerve and establish new 
connections with their physiological targets. The optic nerve has traditionally been thought 
to be incapable of renewal, with axonal damage invariably leading to the degeneration of 
RGC somata and resulting in the irreparable loss of vision. 
A range of studies has investigated the effects of peripheral nerve transplantation on RGC 
survival as well as axonal sprouting and re-growth. Extensive evidence has been presented 
that autologous grafts of peripheral nerves can protect axotomized RGCs from cell death 
and in addition can promote the regeneration and re-growth of axons. Some studies have 
even shown that after transplantation of peripheral nerves, RGCs regenerated long axons, 
which extended into the superior colliculus, where they formed synapses in their 
physiological target region (Aguayo et al., 1991; Vidal-Sanz et al., 1991). 
Other cell types such as OECs and macrophages have been suggested to augment axon 
formation. The promoting effect of OECs on neurite formation may likely be contact-
mediated (Leaver et al., 2006). In addition, macrophages have been reported to promote 
axonal growth, probable through the release of oncomodulin and activation of the protein 
kinase Mst3b and Ca2+/calmodulin kinases as downstream effectors (Lorber et al., 2009 ; Yin 
et al., 2006). 
Distinct growth factors have been identified which may affect optic nerve regeneration. A 
combination of fibroblast growth factor 2 (FGF2), neurotrophin 3 (NT3) and brain derived 
neurotrophic factor (BDNF) (Logan et al., 2006) has been reported to stimulate axonal 
outgrowth of RGCs. Furthermore a range of molecules have been identified, which can 
reduce dendrite formation, e.g. Nogo-A, myelin-associated glycoprotein and components of 
the extracellular matrix such as proteoglycans (Koprivica et al., 2005; Su et al., 2009; Wong et 
al., 2003). Many of these inhibitory factors converge on the small G-protein RhoA, inhibition 
of which has been shown to result in stimulation of axon formation (Bertrand et al., 2005). 
Interestingly, the length of new axons grown from cultured RGCs has been reported to be 
reduced after the developmental age at which synaptic connections in the superior 
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colliculus are formed, although the proportion of cells generating axons was not altered 
(Goldberg et al., 2002). 
The formation and guidance of axons from RGCs to their targets during development have 
been intensively investigated. Netrins, semaphorins, laminin, erythropoietin-producing 
hepatocellular receptor/Eph receptor-interacting protein, Wnt and slits have been shown to 
act as chemo-attractants and repellants during optic nerve development in the embryo 
(Erskine and Herrera, 2007; McLaughlin and O'Leary, 2005). Interestingly, some of these 
guiding signals have been reported to be retained or restored following injury in the adult 
brain (Bahr and Wizenmann, 1996), which may help to guide axons formed by transplanted 
RGCs to the right targets. Additionally it has been shown that following transplantation of 
embryonic retinal tissue, connections to the superior colliculus are successfully established 
(Seiler et al., 2010). 
5. Stem cell mediated neuroprotection in glaucoma 
The pathophysiological mechanisms implicated in RGC loss seen in glaucoma have led to 
the development of neuroprotective strategies becoming a major focus of current glaucoma 
research (Danesh-Meyer, 2011). Contemporary research in stem cell mediated 
neuroprotection for glaucoma has been developed on the backdrop of promising work 
performed in models of neurodegenerative disease affecting other parts of the CNS.  
Glaucomatous RGC loss and neuronal degeneration in other neurodegenerative conditions 
share mechanisms such as oxidative stress, impairment of axonal transport, excitotoxicity 
and inflammation (Baltmr et al., 2010) making neuroprotective strategies relevant to patients 
affected by both conditions. 
Stem cell derived strategies for neuroprotection, if successful, offer several theoretical 
advantages over conventional pharmacological approaches. Should transplanted cells 
integrate within the host retina, it is possible that a single treatment may provide long term 
neuroprotection offering support to surviving neurons. The observation that endogenous 
neural stem cells are able to migrate to the site of injury in ischaemic stroke and differentiate 
into mature neurons (Felling and Levison, 2003), gives rise to the possibility of a similar 
phenomenon occurring with transplanted cells in the context of glaucoma, with such cells 
potentially responsible for the provision of local support. 
Stem cells are able to facilitate local neuronal survival by the production of several 
neurotrophic factors. This multifactorial effect has been demonstrated in animal models of 
CNS disease (Corti et al., 2007) and work in a rodent model of Parkinson’s Disease showed 
that neural stem cell transplantation conferred a more significant neuroprotective benefit 
than both a single injection of neurotrophins or prolonged delivery via local infusion 
(Yasuhara et al., 2006). Transplantation of neural progenitors in animal models of 
neurodegenerative disease has been shown to confer neuroprotection via an 
immunomodulatory mechanism (Pluchino et al., 2005). Alteration of the microenvironment 
surrounding damaged RGCs, perhaps through immune mediated actions of transplanted 
cells, may help promote local neuronal survival. 
A major beacon of hope in stem cell research is the concept of autologous transplantation. 
Such a strategy would minimise the risk of graft rejection and prevent a lifetime of 
potentially toxic immunosuppressive therapy for patients. Neuroprotective strategies 
involving Müller stem cells, bone marrow derived mesenchymal stem cells and OECs offer 
realistic potential for autologous transplantation. However, more work is still necessary to 
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design practical approaches to obtain suitable tissue for this purpose, as well as to derive 
functional cells that can be used for transplantation. Should current concerns regarding the 
safety of iPS cells for therapeutic use be overcome (Jalving and Shepers, 2009), these 
reprogrammed adult somatic cells offer an exciting avenue for the development of 
autologous therapies in the future. 
Mesenchymal stem cell mediated neuroprotection has been demonstrated following 
transplantation in various models of retinal degeneration (Arnhold et al., 2007; Inoue et al., 
2007; Lu et al., 2010; Zhang and Wang, 2010). This phenomenon is likely to be secondary to 
the secretion of neurotrophic factors such as BDNF, ciliary neurotrophic factor (CNTF), 
nerve growth factor (NGF), insulin like growth factor 1 (IGF1) and FGF2 (Cho et al., 2005; 
Labouyrie et al., 1999) which are known to offer protection to damaged retina. These 
observations, coupled with promising results showing neuroprotection in models of CNS 
degenerative disease (Andrews et al., 2008; Karussis et al., 2008; Parr et al., 2007; Torrente 
and Polli, 2008), have led to this category of stem cells becoming a focus for the 
development of cell-based neuroprotective strategies to treat glaucoma. 
Disruption of the retrograde axonal transport of BDNF has been shown to be involved in the 
pathophysiology of glaucoma (Pease et al., 2000) and attempts to upregulate expression of 
BDNF (Martin et al., 2003) and CNTF (Pease et al., 2009) using gene therapy have been 
shown to attenuate RGC loss in experimental models. A reduction in RGC loss has been 
observed in rodents with raised intraocular pressure following intravitreal transplantation 
of mesenchymal stem cells (Johnson et al., 2010a; Yu et al., 2006). The latter reported 
increased levels of CNTF, BDNF and FGF within the retinae of treated eyes, which were 
hypothesised to be responsible for this neuroprotective effect. Survival of the cells was 
observed at up to five weeks, but currently there is a lack of data describing long term graft 
survival and a prolonged neuroprotective effect, both of which will be essential for such a 
therapy to be translated to the clinic.  
Despite suggestions that mesenchymal stem cells may possess a capacity to migrate from 
the systemic circulation into diseased tissue, migration into chronically damaged neural 
tissue is regarded as being limited, and hence strategies for cell delivery would be best 
served by direct injection into affected tissue. In the context of glaucoma models, cells 
administered via an intravenous approach were unable to be detected in the eye and had no 
effect in attenuating RGC loss (Johnson et al., 2010a). 
The neuroprotective effect of transplanted cells may be optimised further by enhancing the 
neurotrophin secreting ability of cells through either cytokine driven protocols or gene 
therapy techniques. Proof of concept for this idea was demonstrated in a model of cerebral 
ischaemia where intravenous infusion of mesenchymal stem cells genetically modified to 
deliver BDNF to the cerebral circulation provided a greater neuroprotective effect than 
untreated cells (Nomura et al., 2005). This principle has been successfully applied to a 
rodent model of RGC damage induced by optic nerve transection (Levkovitch-Verbin et al., 
2010). Mesenchymal stem cells were induced to secrete high levels of BDNF, VEGF and Glial 
Derived Neurotrophic Factor by using a cytokine driven protocol in vitro. Intravitreal 
transplantation of both modified and untreated mesenchymal stem cells produced similar 
neuroprotective effects when compared to sham injection. One interpretation of these 
findings would be that even small amounts of trophic factor release, as seen with untreated 
cells, may confer neuroprotection. However a more realistic argument may be that the 
severity of optic nerve transection is such that even the higher levels of trophic factors 
delivered by the modified cells would be unlikely to prevent RGC death. Further research 
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into the role of cell populations that have enhanced neurotrophin secreting capability in 
models of glaucoma may provide further insight into the therapeutic potential of such an 
approach. 
Inflammation has frequently been associated with neurodegenerative disease. It is 
commonly observed as a consequence of acute injuries including trauma and stroke, but is 
also a characteristic feature of demyelinating disease where autoimmune processes are 
central to the pathophysiology. Mesenchymal stem cells derived from the bone marrow are 
known to have the ability to modulate the inflammatory response. There is much hope and 
optimism in the field of multiple sclerosis that these cells may provide in situ 
immunomodulation and neuroprotection (Payne et al., 2011) with the results of clinical trials 
eagerly awaited. It is quite feasible that this mechanism may be applicable to glaucomatous 
RGC loss, however further studies are required to investigate this possibility. 
The observation that OPCs exhibit neuroprotective properties in vitro (Wilkins et al., 2001) 
has led to some interest in their role as a potential candidate for cell-based therapies in a 
model of glaucoma. Interestingly OPCs were only able to demonstrate a neuroprotective 
effect following concomitant activation of pro-inflammatory cells using zymozan (Bull et al., 
2009). The neuroprotective effect was not contact-mediated and was attributed to the release 
of diffusible trophic factors from the activated OPCs. A potential risk of transplanting such 
cells into glaucomatous eyes is the potential of excessive myelination, which carries the 
theoretical risk of blocking the transmission of light within the eye and reducing the 
electrical conduction of RGCs. However further studies into the nature of the trophic factors 
released by these cells may aid the design of further novel neuroprotective strategies to treat 
glaucoma. 
OEC transplantation has been observed to increase axonal regeneration in models of spinal 
cord injury (Ramon-Cueto and Valverde, 1995). These initial observations led to the 
development of further studies into the potential of these cells to develop novel treatments 
for optic nerve disorders and glaucoma. In vitro work has demonstrated that OECs cause 
ensheathment of RGCs without the process of myelination occurring (Plant et al., 2010). 
Transplantation of OECs into the distal stump of transected optic nerves provided further 
evidence of regeneration of several axons (Li et al., 2003; Wu et al., 2010) that were 
supported by the transplanted cells. Following transretinal delivery into normal rodent eyes, 
OECs migrate along the RGC layer into the optic nervehead demonstrating ensheathment of 
RGC axons by the cytoplasm of transplanted cells (Li et al., 2008). It is possible that this 
process may provide some mechanical support to compromised axons, which may 
subsequently be able to maintain sufficient functional vision if therapies can be developed 
for patients with end stage glaucoma. 
Evidence from models of spinal cord transection suggests that OEC transplantation is 
associated with an increased secretion of neurotrophins such as BDNF which appears to 
correlate with the neuroprotective effect (Sasaki et al., 2006). However it was not clear 
whether the BDNF was secreted by the transplanted cells or by activation of endogenous 
cells. Attempts to combine OEC transplantation with concomitant neurotrophin 
administration have shown promising results to date. Combination therapy in a model of 
optic nerve crush resulted in restoration of the latency of the visual evoked potential to 
almost 90% of normal levels with retrograde RGC labelling suggesting of axonal 
regeneration (Liu et al., 2010).  
Future studies using these cells directed towards attenuating glaucomatous RGC loss may 
focus upon the potential of external support of RGC axons exiting via the lamina cribrosa as 
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well as internal neuroprotection mediated by the provision of trophic factors.  In addition 
further study into the functional characteristics of OECs is required as well as investigation 
of the effects of OEC in models of experimental glaucoma.  
The perfect stem cell-based therapy to treat glaucoma would involve the activation of 
endogenous stem cells to repair damaged RGCs and thus restore function. The damaged 
CNS lacks plasticity and neuronal regeneration is notoriously difficult due to a lack of 
trophic cues (Hou et al., 2008) and the inhibitory nature of the microenvironment (Asher et 
al., 2001). Nevertheless there is growing evidence that endogenous neural stem cells may 
proliferate in response to brain injury such as stroke (Felling and Levison, 2003). Although 
only a proportion of new cells differentiate into new neurons and survive in the long term 
(Naylor et al., 2005), methods have been established to enhance the proliferation of 
endogenous neural stem cells following ischaemic injury (Ninomiya et al., 2006). 
With respect to damaged neurons within the retina, it may be the Müller glia that hold the 
key for endogenous reactivation. Their well-documented capacity to regenerate retinal 
neurons in the teleost retina (Bernardos et al., 2007; Fimbel et al., 2007) and the known 
presence of similar cells in adult human retina (Lawrence et al., 2007) would make these 
cells a promising target around which studies of endogenous stem cell repair could be 
developed. 
6. Conclusion 
The rapidly evolving field of stem cell research offers exciting potential in the long term for 
innovative therapies moving from bench to bedside in patients who are affected by 
advanced glaucoma. Although regeneration of the optic nerve itself may be unrealistic with 
current scientific knowledge, further studies into local retinal ganglion replacement and 
neuroprotective mechanisms using transplanted stem cells may offer hope that such 
treatments may be translated to patients in years to come.  
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